| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Pharmaceutical Research Laboratories III, Pharmaceutical Research Division, Takeda Chemical Industries, Ltd., 17-85 Jusohonmachi 2-chome, Yodogawa-ku, Osaka 532, Japan
The effect of the potent angiogenesis inhibitor O-(chloroacetyl-carbamoyl)fumagillol (TNP-470), a semisynthetic analogue of fumagillin, on tumor growth and metastasis was studied using rodent tumors. Injection of TNP-470 s.c. inhibited tumor growth in a dose-dependent manner, and the tumor sizes of B16BL6 melanoma, M5076 reticulum cell sarcoma, Lewis lung carcinoma, and Walker 256 carcinoma were maximally reduced to 16, 10, 17, and 4% of that in the respective control.
The activity of TNP-470 upon i.v. injection was slightly weaker than that following s.c. injection. This tendency was observed for all the tumors tested. Injection i.v. (infusion) of TNP-470 increased the life span of Walker 256 carcinoma-bearing rats by 183% over the control, while bolus i.v. injection increased the life span by only 47%.
TNP-470 reduced the number of pulmonary metastatic foci of i.v. inoculated B16BL6 melanoma in a dose-dependent manner, and the number of metastatic foci was reduced to 10% of that in the control by treatment with TNP-470 at 60 mg/kg, 3 times/week. The mean survival time of B16BL6 tumor-bearing mice treated with TNP-470 using this regimen was extended by 56% over that of control mice. TNP-470 at 10 mg/kg every day also reduced the number of metastatic foci of M5076 sarcoma in the liver after resection of the tumor from the primary site. Adriamycin at the same dose only slightly reduced the number of metastatic foci, even though TNP-470 and Adriamycin showed roughly equal inhibitory activity against M5076 sarcoma growth. TNP-470 extended the mean survival time of M5076 tumor-bearing mice by more than 100% over that of control mice at 30 mg/kg every 3 days, while Adriamycin extended mean survival times by maximally 20% at 10 mg/kg. These results show that the angiogenesis inhibitor TNP-470 has strong inhibitory activities against in vivo growth and metastasis of a wide variety of tumors.
1 To whom requests for reprints should be addressed.
Received 3/22/93. Accepted 7/ 9/93.
This article has been cited by other articles:
|
|
 |
|
  A. Addlagatta and B. W. Matthews Structure of the angiogenesis inhibitor ovalicin bound to its noncognate target, human Type 1 methionine aminopeptidase Protein Sci., August 1, 2006; 15(8): 1842 - 1848. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Didier, J. N. Phillips, D. J. Kuebler, M. Nasr, P. J. Brindley, M. E. Stovall, L. C. Bowers, and E. S. Didier Antimicrosporidial Activities of Fumagillin, TNP-470, Ovalicin, and Ovalicin Derivatives In Vitro and In Vivo. Antimicrob. Agents Chemother., June 1, 2006; 50(6): 2146 - 2155. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Brakenhielm, R. Cao, B. Gao, B. Angelin, B. Cannon, P. Parini, and Y. Cao Angiogenesis Inhibitor, TNP-470, Prevents Diet-Induced and Genetic Obesity in Mice Circ. Res., June 25, 2004; 94(12): 1579 - 1588. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. W. Nap, A. W. Griffioen, G. A. J. Dunselman, J. C. A. Bouma-Ter Steege, V. L. J. L. Thijssen, J. L. H. Evers, and P. G. Groothuis Antiangiogenesis Therapy for Endometriosis J. Clin. Endocrinol. Metab., March 1, 2004; 89(3): 1089 - 1095. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Huang, J. S. Frischer, T. New, E. S. Kim, A. Serur, A. Lee, A. Kadenhe-Chiwishe, D. A. Pollyea, A. Yokoi, J. Holash, et al. TNP-470 promotes initial vascular sprouting in xenograft tumors Mol. Cancer Ther., March 1, 2004; 3(3): 335 - 343. [Abstract] [Full Text]
|
|
|
|
 |
|
 J. Wang, G. S. Sheppard, P. Lou, M. Kawai, N. BaMaung, S. A. Erickson, L. Tucker-Garcia, C. Park, J. Bouska, Y.-C. Wang, et al. Tumor Suppression by a Rationally Designed Reversible Inhibitor of Methionine Aminopeptidase-2 Cancer Res., November 15, 2003; 63(22): 7861 - 7869. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Tomita, Y. Matsuzaki, M. Edagawa, M. Maeda, T. Shimizu, M. Hara, and T. Onitsuka Correlation between tumor angiogenesis and invasiveness in thymic epithelial tumors J. Thorac. Cardiovasc. Surg., September 1, 2002; 124(3): 493 - 498. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Ma, S. Pulfer, S. Li, J. Chu, K. Reed, and J. M. Gallo Pharmacodynamic-mediated Reduction of Temozolomide Tumor Concentrations by the Angiogenesis Inhibitor TNP-470 Cancer Res., July 1, 2001; 61(14): 5491 - 5498. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. J. Logothetis, K. K. Wu, L. D. Finn, D. Daliani, W. Figg, H. Ghaddar, and J. U. Gutterman Phase I Trial of the Angiogenesis Inhibitor TNP-470 for Progressive Androgen-independent Prostate Cancer Clin. Cancer Res., May 1, 2001; 7(5): 1198 - 1203. [Abstract] [Full Text]
|
|
|
|
|
|
C.-N. Chen, Y.-M. Cheng, J.-T. Liang, P.-H. Lee, F.-J. Hsieh, R.-H. Yuan, S.-M. Wang, M.-F. Chang, and K.-J. Chang Color Doppler Vascularity Index Can Predict Distant Metastasis and Survival in Colon Cancer Patients Cancer Res., June 1, 2000; 60(11): 2892 - 2897. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. W. Griffioen and G. Molema Angiogenesis: Potentials for Pharmacologic Intervention in the Treatment of Cancer, Cardiovascular Diseases, and Chronic Inflammation Pharmacol. Rev., June 1, 2000; 52(2): 237 - 268. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. A. Drixler, I. H. M. B. Rinkes, E. D. Ritchie, T. J. M. V. van Vroonhoven, M. F. B. G. Gebbink, and E. E. Voest Continuous Administration of Angiostatin Inhibits Accelerated Growth of Colorectal Liver Metastases after Partial Hepatectomy Cancer Res., March 1, 2000; 60(6): 1761 - 1765. [Abstract] [Full Text]
|
|
|
|
 |
|
 U. Jäger, Y. Zhao, and C. D. Porter Endothelial Cell-Specific Transcriptional Targeting from a Hybrid Long Terminal Repeat Retrovirus Vector Containing Human Prepro-Endothelin-1 Promoter Sequences J. Virol., December 1, 1999; 73(12): 9702 - 9709. [Abstract] [Full Text]
|
|
|
|
 |
|
 J. Liu, B. Razani, S. Tang, B. I. Terman, J. A. Ware, and M. P. Lisanti Angiogenesis Activators and Inhibitors Differentially Regulate Caveolin-1 Expression and Caveolae Formation in Vascular Endothelial Cells. ANGIOGENESIS INHIBITORS BLOCK VASCULAR ENDOTHELIAL GROWTH FACTOR-INDUCED DOWN-REGULATION OF CAVEOLIN-1 J. Biol. Chem., May 28, 1999; 274(22): 15781 - 15785. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Moses, D. Wiederschain, I. Wu, C. A. Fernandez, V. Ghazizadeh, W. S. Lane, E. Flynn, A. Sytkowski, T. Tao, and R. Langer Troponin I is present in human cartilage and inhibits angiogenesis PNAS, March 16, 1999; 96(6): 2645 - 2650. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. P. Kudelka, C. F. Verschraegen, and E. Loyer Complete Remission of Metastatic Cervical Cancer with the Angiogenesis Inhibitor TNP-470 N. Engl. J. Med., April 2, 1998; 338(14): 991 - 992. [Full Text]
|
|
|
|
 |
|
 K. R. Dover and A. W. Valley Review : Angiogenesis: A new target for antineoplastic therapy Journal of Oncology Pharmacy Practice, January 1, 1996; 2(1): 43 - 60. [Abstract] [PDF]
|
|
|
|
 |
|
 P. Brooks, R. Clark, and D. Cheresh Requirement of vascular integrin alpha v beta 3 for angiogenesis Science, April 22, 1994; 264(5158): 569 - 571. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
